By a News Reporter-Staff News Editor at Vaccine Weekly -- Current study results on Immunization have been published. According to news reporting originating from Springfield, Missouri, by NewsRx correspondents, research stated, "Nanoparticle conjugates have the potential for delivering siRNA, splice-shifting oligomers or nucleic acid vaccines, and can be applicable to anticancer therapeutics. This article compares tripartite conjugates with gold nanoparticles or synthetic methoxypoly(ethylene glycol)-block-polyamidoamine dendrimers."
Our news editors obtained a quote from the research from Missouri State University, "Interactions with model liposomes of a 1:1 molar ratio of tripalmitin:cholesterol or phospholipid:cholesterol were investigated by high-throughput absorbance, as well as fluorescence difference and cellular luminescence assays. Spectral differences and dynamic light-scattering spectroscopy shifts demonstrated the interaction of conjugates with liposomes. Biological activity was demonstrated by upregulation of gene expression via splice-shifting oligomers, delivery of anti-B-Raf siRNA in cultured human cancer cells or tuberculosis antigen 85B plasmid expression vector in a coculture model of antigen presentation."
According to the news editors, the research concluded: "The data suggests that gold nanoparticles and methoxypoly(ethylene glycol)-block-polyamidoamine dendrimer nanoconjugates may have potential for binding, stabilization and delivery of splice-shifting oligomers, siRNA and nucleic acid vaccines for preclinical trials."
For more information on this research see: Characterization of biomolecular nanoconjugates by high-throughput delivery and spectroscopic difference. Nanomedicine, 2012;7(12):1851-62. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)
The news editors report that additional information may be obtained by contacting R.K. Delong, Missouri State University, Cell & Molecular Biology Program, Springfield, MO 65897, United States. Additional authors for this research include A. Risor, M. Kanomata, A. Laymon, B. Jones, S.D. Zimmerman, J. Williams, C. Witkowski, M. Warner, M. Ruff, R. Garrad, J.K. Fallon, A.J. Hickey and R. Sedaghat-Herati (see also Immunization).
Keywords for this news article include: Missouri, Vaccines, Springfield, Immunization, Therapeutics, United States, Nanoconjugates, Nanotechnology, Gold Nanoparticles, Pre Trial Research, Biological Products, Emerging Technologies, North and Central America, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC